Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells

Table 1 Effect of intravitreal injection of PP-001 on R14-induced relapsing EAU in rats

	Vehicle	PP-001
Mean max. clin. uveitis score primary disease (score 0 – 4 ± SE)	2.6 ± 0.1	2.7 ± 0.1
Mean max. clin. uveitis score at day of injection (score 0 – 4 ± SE)	0.5 ± 0.1	0.4 ± 0.1
Total no. of relapses post injection until day 6	20	6
No. of eyes with multiple relapses	2	0
No. of eyes with relapses	18 out of 30 eyes (60%)*	6 out of 29 eyes (21%)*
Relapses/animals	11/15 (73%)*	5/15 (33%)*
Mean max. uveitis score/relapse (score 0 – 4 ± SE)	1.1 ± 0.1	1.2 ± 0.3
Mean duration of relapse (days ± SE)	1.45 ± 0.11	1.17 ± 0.17
Mean appearance of first relapse (days post injection ± SE)	3.4 ± 0.5	4.3 ± 0.9
Mean severity of uveitis post injection until day 6 (± SE)	2.22 ± 0.25*	1.34 ± 0.22*

“Mean severity of uveitis” is the mean of daily uveitis scores calculated over a certain period of time. One eye of the PP-001-treated group (rat 7/PP-001, see Fig. 1) was perforated during injection and not considered. Data are pooled from two independent experiments, Exp. 1, n = 10; Exp. 2, n = 5 rats/group. *p < 0.05

ISSN: 1742-2094